Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells

Cellular Immunology

Volumn 258, Issue 1, 2009, Pages 18-28

  Bancos, Simona ^a   Bernard, Matthew P ^a   Topham, David J ^a   Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Antibody; Cox 2; Human B lymphocytes; NSAIDs

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; DRUG USE; ELDERLY CARE; ENZYME INDUCTION; ENZYME REGULATION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; IBUPROFEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, KNOCKOUT; PYRAZOLES;

EID: 67349120253     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.03.007     Document Type: Article

References (39)

1. Dai C., Stafford R.S., and Alexander G.C. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch. Intern. Med. 165 (2005) 171-177
2. Kawamori T., Uchiya N., Sugimura T., and Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24 (2003) 985-990
3. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
4. Chiroli S., Chinellato A., Didoni G., Mazzi S., and Lucioni C. Utilisation pattern of nonspecific nonsteroidal anti-inflammatory drugs and COX-2 inhibitors in a Local Health Service Unit in Northeast Italy. Clin. Drug Investig. 23 (2003) 751-760
5. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345 (2001) 433-442
6. Cryer B., and Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104 (1998) 413-421
7. Purcell P., Henry D., and Melville G. Diclofenac hepatitis. Gut 32 (1991) 1381-1385
8. Fored C.M., Ejerblad E., Lindblad P., Fryzek J.P., Dickman P.W., Signorello L.B., Lipworth L., Elinder C.G., Blot W.J., McLaughlin J.K., Zack M.M., and Nyren O. Acetaminophen, aspirin, and chronic renal failure. N. Engl. J. Med. 345 (2001) 1801-1808
9. Nguyen H.T., and Juurlink D.N. Recurrent ibuprofen-induced aseptic meningitis. Ann. Pharmacother. 38 (2004) 408-410
10. Wheeler P., and Batt M. Do non-steroidal anti-inflammatory drugs adversely affect stress fracture healing?. Br. J. Sport Med. 39 (2005) 65-69
11. Cryer B., and Kimmey M.B. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am. J. Med. 105 (1998) 20S-30S
12. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., and Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 (2005) 1092-1102
13. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., and Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352 (2005) 1071-1080
14. Inigues M., Punzon C., and Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J. Immunol. 163 (1999) 111-119
15. Paccani S.R., Boncristiano M., Ulivieri C., D'Elios M.M., Del Prete G., and Baldari C.T. Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J. Biol. Chem. 277 (2002) 1509-1513
16. Hartel C., von Puttkamer J., Gallner F., Strunk T., and Schultz C. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition. Scand. J. Immunol. 60 (2004) 412-420
17. Ryan E.P., Pollock S.J., Murant T.I., Bernstein S.H., Felgar R.E., and Phipps R.P. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J. Immunol. 174 (2005) 2619-2626
18. Bernard M.P., and Phipps R.P. CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production. Clin. Immunol. 125 (2007) 138-148
19. Emori H.W., Bluestone R., Champion G.D., and Pearson C. Indomethacin serum concentrations in man. Effects of dosage, food, and antacid. Ann. Rheum. Dis. 35 (1973) 333-338
20. Whitlam J.B., Brown K.F., Crooks M.J., and Room G.F. Transsynovial distribution of ibuprofen in arthritic patients. Clin. Pharmacol. Ther. 29 (1981) 487-492
21. Blain H., Boileau C., Lapicque F., Nedelec E., Loeuille D., Guillaume C., Gaucher A., Jeandel C., Netter P., and Jouzeau J.Y. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br. J. Clin. Pharmacol. 53 (2002) 255-265
22. Rainsford K.D. Aspirin and Related Drugs (2004), CRC Press, London
23. Pernerstorfer T., Schmid R., Bieglmayer C., Eichler H.G., Kapiotis S., and Jilma B. Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. Clin. Pharmacol. Ther. 66 (1999) 51-57
24. Gelotte C.K., Auiller J.F., Lynch M., Temple A.R., and Slattery J.T. Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin. Pharmacol. Ther. 81 (2007) 840-848
25. Capone M.L., Tacconelli S., Di Francesco L., Sacchetti A., Sciulli M.G., and Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostag. Other Lipid Mediat. 82 (2007) 85-94
26. Davies P., Bailey P.J., Goldenberg M.M., and Ford-Hutchinson A.W. The role of arachidonic acid oxygenation products in pain and inflammation. Annu. Rev. Immunol. 2 (1984) 335-357
27. Neupert W., Brugger R., Euchenhofer C., Brune K., and Geisslinger G. Effects of ibuprofen enantiomers, its coenzyme A thioesters on human prostaglandin endoperoxide synthases. Br. J. Pharmacol. 122 (1997) 487-492
28. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, Br. Med. J. 324 (2002) 71-86.
29. Loll P.J., Picot D., and Garavito R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 2 (1995) 637-643
30. Borthwick G.M., Johnson A.S., Partington M., Burn J., Wilson R., and Arthur H.M. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J. 20 (2006) 2009-2016
31. Ouellet M., and Percival M.D. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch. Biochem. Biophys. 387 (2001) 273-280
32. Lucas R., Warner T.D., Vojnovic I., and Mitchell J.A. Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J. 19 (2005) 635-637
33. http://www.tylenolprofessional.com, published by McNeil Consumer Healthcare, a Division of McNEIL-PPC, Inc.
34. Moore N. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin. Drug Investig. 27 (2007) 163-195
35. Hay A.D., Costelloe C., Redmond N.M., Montgomery A.A., Fletcher M., Hollinghurst S., and Peters T.J. Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. Br. Med. J. 337 (2008) a1302
36. Sanins M., Adams W.J., Kaiser D.G., Halstead G.W., and Baillie T.A. Studies on the metabolism and chiral inversion of ibuprofen in isolated rat hepatocytes. Drug Metab. Dispos. 18 (1990) 527-533
37. Janssen A., Maier T.J., Schiffmann S., Coste O., Seegel M., Geisslinger G., and Grosch S. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur. J. Pharmacol. 540 (2006) 24-33
38. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 23 (2002) 144-150
39. Ryan E.P., Malboeuf C.M., Bernard M., Rose R.C., and Phipps R.P. Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J. Immunol. 177 (2006) 7811-7819